Advanced search
Publication Cover
Expert Review of Vaccines Volume 2, 2003 - Issue 1
Submit an article Journal homepage
137
Views
61
CrossRef citations to date
0
Altmetric
Review

Bacterial ghosts as carrier and targeting systems for mucosal antigen delivery

Katri Jalava BIRD-C GmbH & CoKEG, Schoenborngasse 12, A-1080 Wien, Austria
,
Francis O Eko Department of Microbiology, Biochemistry and Immunology, Morehouse School of Medicine, Atlanta, GA, USA
,
Eva Riedmann Institute of Microbiology and Genetics, University of Vienna, Austria
&
Werner Lubitz BIRD-C GmbH & CoKEG, Schoenborngasse 12, A-1080 Wien, Austria and Institute of Microbiolgy and Genetics, University of Vienna, Austria
Pages 45-51 | Published online: 09 Jan 2014

References

  • Witte A, Wanner G, Blasi U, Halfmann G, Szostak M, Lubitz W Endogenous transmembrane tunnel formation mediated by phi X174 lysis protein E. J. Bacterial 172(7), 4109–4114. (1990).
  • •• Excellent electronmicrographs of bacterial ghosts.
  • Witte A, Blasi U, Halfmann G, Szostak M, Wanner G, Lubitz W Phi X174 protein E-mediated lysis of Echerichia coil Biochimie 72(2–3), 191–200 (1990).
  • Witte A, Wanner G, Sulzner M, Lubitz W Dynamics of PhiX174 protein E-mediated lysis of Echerichia coil Arch. Mcrobiol 157(4), 381–388 (1992).
  • Witte A, Brand E, Schrot G, Lubitz W Pathway of PhiX174 protein E mediated lysis of Echerichia coil In: Bacterial growth and lysis. de Pedro MA, Holtje J-V, Löffelhardt W (Eds). Plenum Press, New York, NY, USA (1993).
  • Lubitz W Pugsley AR Changes in host cell phospholipid composition of PhiX 174 gene Eproduct. FEMS Mcrobiol. Lett. 30,171-175 (1985).
  • Witte A, Brand E, Mayrhofer P, Narendja F, Lubitz W Dependence of PhiX174 protein E-mediated lysis on cell division activities of Escherichia coil Arch. Mcrobiol. 170,259–268 (1998).
  • Szostak MP, Hensel A, Eko FO etal. Bacterial ghosts: non-living candidate vaccines. J. Biotechnol 44(1–3), 161–170 (1996).
  • Kloos DU, Stratz M, Guttler A, Steffan RJ, Timmis KN. Inducible cell lysis system for the study of natural transformation and environmental fate of DNA released by cell death. J. Bacteria 176(23), 7352–7361 (1994).
  • Ronchel MC, Molina L, Witte A eta,'. Characterization of cell lysis in Pseudomonas putida induced upon expression of heterologous killing genes. Appl Mavbiol 64(12), 4904–4911 (1998).
  • Jechliriger W Szostak MP, Witte Lubitz A. W Altered temperature induction sensitivity of the lambda pR/cI857 system for controlled gene E expression in Escherichia coil FEMS Mcrobiol. Lett. 173(2), 347–352 (1999).
  • •Novel system for temperature-induced gene expression.
  • Jechlinger W Szostak MP, Lubitz W Cold-sensitive E-lysis systems. Gene 218(1–2), 1–7 (1998).
  • Haidinger W Szostak MP, Beisker W Lubitz W Green fluorescent protein (GFP)-dependent separation of bacterial ghosts from intact cells by FACS. Cytometry 44(2), 106–112 (2001).
  • Haidinger W Mayr UB, Szostak M, Resch Lubitz, S. W Echerichia coil ghost production by expression of lysis gene Rand staphylococcal nuclease. (In Press) (2002).
  • Haidinger W Szostak M, Jechlinger W Lubitz W Online monitoring of the Echerichia cob ghost production. Appl Environ. Mcrobiol. In Press (2002).
  • Resch S, Gruber K, Wanner G, Slater S, Dennis D, Lubitz W Aqueous release and purification of poly (beta-hydroxybutyrate) from Echerichia coil j Biotechnol 65 (2–3), 173–182 (1998).
  • Hensel A, Lubitz W Vaccination by aerosols: modulation of clearance mechanisms in the lung. Behring Inst. Mitt. (98), 212–219 (1997).
  • Hensel A, van Leengoed LA, Szostak M etal. Induction of protective immunity by aerosol or oral application of candidate vaccines in a dose-controlled pig aerosol infection model. J. Biotechnol 44(1-3), 171–181 (1996).
  • Katinger A, Lubitz W Szostak MP etal. Pigs aerogenously immunized with genetically inactivated (ghosts) or irradiated Actinobacillus pleuropneumoniae are protected against a homologous aerosol challenge despite differing in pulmonary cellular and antibody responses. J. Biotechnol 73(2–3), 251–260 (1999).
  • Hensel A, Huter V, Katinger A Intramuscular immunization with genetically inactivated (ghosts) Actinobacillus pleuropneumoniae serotype 9 protects pigs against homologous aerosol challenge and prevents carrier state. Vaccine 18(26), 2945–2955 (2000).
  • Huter V, Hensel A, Brand E, Lubitz W Improved protection against lung colonization by Actinobacillus pleuropneumoniae ghosts: characterization of a genetically inactivated vaccine. J. Biotechnol 83(1-2), 161–172 (2000).
  • Haslberger AG, Kohl G, Felnerova D, Mayr UB, Furst-Ladani S, Lubitz W Activation, stimulation and uptake of bacterial ghosts in antigen-presenting cells. J. Biotechnol 83(1-2), 57–66 (2000).
  • Clemens JD, Sack DA, Harris JR Field trial of oral cholera vaccines in Bangladesh: results from three-year follow-up. Lancet 335(8684), 270–273 (1990).
  • Eko FO, Mayr UB, Attridge SR, Lubitz W Characterization and immunogenicity of Vibrio cholerae ghosts expressing toxin-coregulated pili. Biotechnol 83(1-2), 115–123 (2000).
  • Eko FO, Schukovskaya T, Lotzmanova EY etal. Evaluation of the protective efficacy of Vibrio cholerae ghosts (VCG) candidate vaccines in rabbits. In Press (2002).
  • Panthel K, Jechlinger W Matis A etal. Generation of Helicobacter pylori ghosts by PhiX E-mediated inactivation and their evaluation as vaccine candidates. Infect. Immun 71(1), In Press (2003).
  • Mader HJ, Szostak MP, Hensel A, Lubitz W Haslberger AG. Endotoxicity does not limit the use of bacterial ghosts as candidate vaccines. Vaccine 15(2), 195–202 (1997).
  • Haslberger AG, Mader HJ, Schmalnauer M etal. Bacterial cell envelopes (ghosts) and LPS but not bacterial S-layers induce synthesis of immune-mediators in mouse macrophages involving CD14. j Endotox. Res. 4,431-441 (1997).
  • Szostak M, Lubitz W Recombinant bacterial ghosts as multivaccine vehicles. In: Modern approaches to new vaccines including prevention of AIDS, Vaccines 91. Chanock R, (Ed.). Cold Spring Harbor Laboratory Press, New York, NY, USA (1991).
  • Lubitz W Witte Eko, A. FO et al. Extended recombinant bacterial ghost system. J. Biotechnol. 73(2-3), 261–273 (1999).
  • Eko FO, Witte A, Huter V . New strategies for combination vaccines based on the extended recombinant bacterial ghost system. Vaccine 17(13-14), 1643–1649 (1999).
  • Huter V, Szostak MP, Gampfer J etal. Bacterial ghosts as drug carrier and targeting vehicles. J. Control Release 61(1—, 51–63 (1999). First report of filling bacterial ghosts.
  • Kuen B, Sleytr UB, Lubitz W Sequence analysis of the sbsA gene encoding the 130-kDa surface-layer protein of Bacillus stearothermophilus strain PV72. Gene 145(1), 115–120 (1994).
  • Kuen B, Sara M, Lubitz W Heterologous expression and self-assembly of the S-layer protein SbsA of Bacillus stearothermophilus in Escherichia coll. Mol M'crobiol. 19(3), 495–503 (1996).
  • Kuen B, Koch A, Asenbauer E, Sara M, Lubitz W Molecular characterization of the Bacillus stearothermophilus PV72 S-layer gene sbsB induced by oxidative stress. J. Bacteria 179(5), 1664–1670 (1997).
  • Truppe M, Howorka S, Schroll G et al. Biotechnological applications of recombinant S-layer proteins rSbsA and rSbsB from Bacillus steamthennophilus PV72. FEMS Mcrobia Rev 20,47–98 (1997).
  • Howorka S, Sara M, Wang Y etal. Surface- accessible residues in the monomeric and assembled forms of a bacterial surface layer protein. J. Biol. Chem. 275(48), 37876–37886 (2000).
  • Riedmann E, Kyd JM, Smith AM etal. Construction of recombinant S-layer proteins (rSbsA) and their expression in bacterial ghosts — a delivery system for the nontypeable liaemophilus intkenzae antigen Omp26. In Press (2002).
  • Schätzlein AG, Uchegbu IE Non-viral vectors in gene delivery. Drug Deily Systems Li. 1,17–23 (2001).
  • Igietseme JU, Black CM, Caldwell HD. Chlamydia vaccines: strategies and status. BioDrugs16(1), 19–35 (2002).
  • Eko FO, Lubitz W Igietseme JU. Immunogenicity of a novel recombinant subunit candidate vaccine against Chlamydia trachomatis ASM General Meeting Orlando, FL, USA (2001).
  • Eko FO, Lubitz W Mcmillan L etal. Recombinant Vibrio cholerae ghosts as a delivery vehicle for vaccinating against Chlamydia trachomatis Vaccine 3591, In Press (2002).
  • Paterson M, Jennings ZA, van Duin M, Aitken RJ. Immunocontraception with zona pellucida proteins. Cells Tissues Organs 166(2), 228–232 (2000).
  • Duckworth J, Mate K, Scobie S et al. Evaluating zona pellucida antigens and delivery systems for possum fertility control in New Zealand - progress and future directions. In: Biological management of possums: National Science Strategy Committee for Possum and Bovine Tb Control, April 2–4, 2001. Wellington, New Zealand, Ministry of Agriculture and Forestry, www.maf.gov.nz/mafnet/ publications/research/biological-management-of-possums (2001).
  • Witte A, Wanner G, Blasi U, Halfmann G, Szostak M, Lubitz W Endogenous transmembrane tunnel formation mediated by phi X174 lysis protein E. J. Bacterial 172(7), 4109–4114. (1990).
  • •• Excellent electronmicrographs of bacterial ghosts.
  • Witte A, Blasi U, Halfmann G, Szostak M, Wanner G, Lubitz W Phi X174 protein E-mediated lysis of Echerichia coil Biochimie 72(2–3), 191–200 (1990).
  • Witte A, Wanner G, Sulzner M, Lubitz W Dynamics of PhiX174 protein E-mediated lysis of Echerichia coil Arch. Mcrobiol 157(4), 381–388 (1992).
  • Witte A, Brand E, Schrot G, Lubitz W Pathway of PhiX174 protein E mediated lysis of Echerichia coil In: Bacterial growth and lysis. de Pedro MA, Holtje J-V, Löffelhardt W (Eds). Plenum Press, New York, NY, USA (1993).
  • Lubitz W Pugsley AR Changes in host cell phospholipid composition of PhiX 174 gene Eproduct. FEMS Mcrobiol. Lett. 30,171-175 (1985).
  • Witte A, Brand E, Mayrhofer P, Narendja F, Lubitz W Dependence of PhiX174 protein E-mediated lysis on cell division activities of Escherichia coil Arch. Mcrobiol. 170,259–268 (1998).
  • Szostak MP, Hensel A, Eko FO etal. Bacterial ghosts: non-living candidate vaccines. J. Biotechnol 44(1–3), 161–170 (1996).
  • Kloos DU, Stratz M, Guttler A, Steffan RJ, Timmis KN. Inducible cell lysis system for the study of natural transformation and environmental fate of DNA released by cell death. J. Bacteria 176(23), 7352–7361 (1994).
  • Ronchel MC, Molina L, Witte A eta,'. Characterization of cell lysis in Pseudomonas putida induced upon expression of heterologous killing genes. Appl Mavbiol 64(12), 4904–4911 (1998).
  • Jechliriger W Szostak MP, Witte Lubitz, A. W Altered temperature induction sensitivity of the lambda pR/cI857 system for controlled gene E expression in Escherichia coil FEMS Mcrobiol. Lett. 173(2), 347–352 (1999).
  • •Novel system for temperature-induced gene expression.
  • Jechlinger W Szostak MP, Lubitz W Cold-sensitive E-lysis systems. Gene 218(1–2), 1–7 (1998).
  • Haidinger W Szostak MP, Beisker W Lubitz W Green fluorescent protein (GFP)-dependent separation of bacterial ghosts from intact cells by FACS. Cytometry 44(2), 106–112 (2001).
  • Haidinger W Mayr UB, Szostak M, Resch Lubitz, S. W Echerichia coil ghost production by expression of lysis gene Rand staphylococcal nuclease. (In Press) (2002).
  • Haidinger W Szostak M, Jechlinger W Lubitz W Online monitoring of the Echerichia cob ghost production. Appl Environ. Mcrobiol. In Press (2002).
  • Resch S, Gruber K, Wanner G, Slater S, Dennis D, Lubitz W Aqueous release and purification of poly (beta-hydroxybutyrate) from Echerichia coil j Biotechnol 65 (2–3), 173–182 (1998).
  • Hensel A, Lubitz W Vaccination by aerosols: modulation of clearance mechanisms in the lung. Behring Inst. Mitt. (98), 212–219 (1997).
  • Hensel A, van Leengoed LA, Szostak M etal. Induction of protective immunity by aerosol or oral application of candidate vaccines in a dose-controlled pig aerosol infection model. J. Biotechnol 44(1-3), 171–181 (1996).
  • Katinger A, Lubitz W Szostak MP etal. Pigs aerogenously immunized with genetically inactivated (ghosts) or irradiated Actinobacillus pleuropneumoniae are protected against a homologous aerosol challenge despite differing in pulmonary cellular and antibody responses. J. Biotechnol 73(2–3), 251–260 (1999).
  • Hensel A, Huter V, Katinger A et al Intramuscular immunization with genetically inactivated (ghosts) Actinobacillus pleuropneumoniae serotype 9 protects pigs against homologous aerosol challenge and prevents carrier state. Vaccine 18(26), 2945–2955 (2000).
  • Huter V, Hensel A, Brand E, Lubitz W Improved protection against lung colonization by Actinobacillus pleuropneumoniae ghosts: characterization of a genetically inactivated vaccine. J. Biotechnol 83(1-2), 161–172 (2000).
  • Haslberger AG, Kohl G, Felnerova D, Mayr UB, Furst-Ladani S, Lubitz W Activation, stimulation and uptake of bacterial ghosts in antigen-presenting cells. J. Biotechnol 83(1-2), 57–66 (2000).
  • Clemens JD, Sack DA, Harris JR et al Field trial of oral cholera vaccines in Bangladesh: results from three-year follow-up. Lancet 335(8684), 270–273 (1990).
  • Eko FO, Mayr UB, Attridge SR, Lubitz W Characterization and immunogenicity of Vibrio cholerae ghosts expressing toxin-coregulated pili. Biotechnol 83(1-2), 115–123 (2000).
  • Eko FO, Schukovskaya T, Lotzmanova EY etal. Evaluation of the protective efficacy of Vibrio cholerae ghosts (VCG) candidate vaccines in rabbits. In Press (2002).
  • Panthel K, Jechlinger W Matis A etal. Generation of Helicobacter pylori ghosts by PhiX E-mediated inactivation and their evaluation as vaccine candidates. Infect. Immun 71(1), In Press (2003).
  • Mader HJ, Szostak MP, Hensel A, Lubitz W Haslberger AG. Endotoxicity does not limit the use of bacterial ghosts as candidate vaccines. Vaccine 15(2), 195–202 (1997).
  • Haslberger AG, Mader HJ, Schmalnauer M etal. Bacterial cell envelopes (ghosts) and LPS but not bacterial S-layers induce synthesis of immune-mediators in mouse macrophages involving CD14. j Endotox. Res. 4,431-441 (1997).
  • Szostak M, Lubitz W Recombinant bacterial ghosts as multivaccine vehicles. In: Modern approaches to new vaccines including prevention of AIDS, Vaccines 91. Chanock R, (Ed.). Cold Spring Harbor Laboratory Press, New York, NY, USA (1991).
  • Lubitz W Witte Eko, A. FO etal. Extended recombinant bacterial ghost system. J. Biotechnol. 73(2-3), 261–273 (1999).
  • Eko FO, Witte A, Huter V et al. New strategies for combination vaccines based on the extended recombinant bacterial ghost system. Vaccine 17(13-14), 1643–1649 (1999).
  • Huter V, Szostak MP, Gampfer J etal. Bacterial ghosts as drug carrier and targeting vehicles. J. Control Release 61(1—, 51–63 (1999). First report of filling bacterial ghosts.
  • Kuen B, Sleytr UB, Lubitz W Sequence analysis of the sbsA gene encoding the 130-kDa surface-layer protein of Bacillus stearothermophilus strain PV72. Gene 145(1), 115–120 (1994).
  • Kuen B, Sara M, Lubitz W Heterologous expression and self-assembly of the S-layer protein SbsA of Bacillus stearothermophilus in Escherichia coll. Mol M'crobiol. 19(3), 495–503 (1996).
  • Kuen B, Koch A, Asenbauer E, Sara M, Lubitz W Molecular characterization of the Bacillus stearothermophilus PV72 S-layer gene sbsB induced by oxidative stress. J. Bacteria 179(5), 1664–1670 (1997).
  • Truppe M, Howorka S, Schroll G et al. Biotechnological applications of recombinant S-layer proteins rSbsA and rSbsB from Bacillus steamthennophilus PV72. FEMS Mcrobia Rev 20,47–98 (1997).
  • Howorka S, Sara M, Wang Y etal. Surface- accessible residues in the monomeric and assembled forms of a bacterial surface layer protein. J. Biol. Chem. 275(48), 37876–37886 (2000).
  • Riedmann E, Kyd JM, Smith AM etal. Construction of recombinant S-layer proteins (rSbsA) and their expression in bacterial ghosts — a delivery system for the nontypeable liaemophilus intkenzae antigen Omp26. In Press (2002).
  • Schätzlein AG, Uchegbu IE Non-viral vectors in gene delivery. Drug Deily Systems Li. 1,17–23 (2001).
  • Igietseme JU, Black CM, Caldwell HD. Chlamydia vaccines: strategies and status. BioDrugs16(1), 19–35 (2002).
  • Eko FO, Lubitz W Igietseme JU. Immunogenicity of a novel recombinant subunit candidate vaccine against Chlamydia trachomatis ASM General Meeting Orlando, FL, USA (2001).
  • Eko FO, Lubitz W Mcmillan L etal. Recombinant Vibrio cholerae ghosts as a delivery vehicle for vaccinating against Chlamydia trachomatis Vaccine 3591, In Press (2002).
  • Paterson M, Jennings ZA, van Duin M, Aitken RJ. Immunocontraception with zona pellucida proteins. Cells Tissues Organs 166(2), 228–232 (2000).

Websites

  • Duckworth J, Mate K, Scobie S et al. Evaluating zona pellucida antigens and delivery systems for possum fertility control in New Zealand - progress and future directions. In: Biological management of possums: National Science Strategy Committee for Possum and Bovine Tb Control, April 2–4, 2001. Wellington, New Zealand, Ministry of Agriculture and Forestry, www.maf.gov.nz/mafnet/ publications/research/biological-management-of-possums (2001).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.